Tetrathiomolybdate in Hormone Refractory Prostate Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00150995|
Recruitment Status : Completed
First Posted : September 8, 2005
Last Update Posted : January 21, 2015
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer||Drug: Tetrathiomolybdate||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||19 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Trail of Tetrathiomolybdate in Patients With Hormone Refractory Prostate Cancer|
|Study Start Date :||May 2001|
|Actual Primary Completion Date :||October 2003|
|Actual Study Completion Date :||April 2006|
Patients will be started on a dose of 60mg Tetrathiomolybdate at bedtime and 40mg 3 times per day.
- Time to Progression [ Time Frame: 12 weeks ]To determine the time to progression of prostate cancer in patients with androgen-independent prostate cancer treated with tetrathiomolybdate. Disease progression is defined as at least a 20% increase in the sum of the longest diameter of the target lesions. For disease evaluable only by bone scan, the appearance of new lesions was considered evidence of progression. The development of pain in an existing lesion requiring institution of palliative radiotherapy or prescription narcotics was also considered evidence of progression.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00150995
|United States, Michigan|
|The University of Michigan Comprehensive Cancer Center|
|Ann Arbor, Michigan, United States, 48109|
|Principal Investigator:||David C. Smith, MD||The University of Michigan Comprehensive Cancer Center|